Promising drug cocktail targets Hard-to-Treat ovarian cancer
NCT ID NCT06494150
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of nab-sirolimus (Fyarro) and fulvestrant (Faslodex) in 37 people with recurrent low-grade serous ovarian cancer. The goal is to see if the drugs can shrink tumors or stop them from growing. Participants receive the drugs intravenously and by injection over 21-day cycles, and researchers will track response rates and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nab-sirolimus (Fyarro) and fulvestrant (Faslodex)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with recurrent low-grade serous ovarian cancer, potentially slowing or shrinking tumors.
- What could go wrong
- This is a small, early-phase study with only 37 participants, so results may not apply to everyone. Side effects from the drugs could be serious, and the treatment may not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOW GRADE OVARIAN SEROUS ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, 73117, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.